Published in Vaccine Weekly, March 1st, 1999
In this study, A.B. McDermott and colleagues investigated the effects of single pre-S/S (Hepagene) revaccination in a large population of multiple 'S' vaccinated anti-HBs antibody nonresponder individuals (< 3 IU/l). Hepagene is a registered trademark of Hedeva Pharma Ltd.
"We investigated the influence of vaccine dose (5, 10, 20, and 40 micrograms/ml), number of previous 'S' containing vaccinations and the individuals HLA genotype on both B- and T-cell responses." McDermott et al. wrote ("Human Leukocyte Antigens...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly